Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 13/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 9/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 9/20 | 0.40 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL120715 | 1.00 | MME (0.44) | MMEACECPA1ACE2DPP4 | |
| SCHEMBL8723093 | 0.85 | MME (0.62) | MMEACECPA1ACE2DPP4 | |
| SCHEMBL8723097 | 0.85 | MME (0.62) | MMEACECPA1ACE2DPP4 | |
| SCHEMBL15663557 | 0.85 | MME (0.62) | MMEACECPA1ACE2DPP4 | |
| SCHEMBL18822411 | 0.83 | DPP4 (0.42) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL15700570 | 0.82 | ALDH1A1 (0.46) | MMEACECPA1ACE2DPP4 | |
| SCHEMBL29886647 | 0.81 | MME (0.59) | MMEACECPA1ACE2DPP4 | |
| SCHEMBL27343659 | 0.81 | BIRC2 (0.42) | MMEACECPA1ACE2DPP4 | |
| SCHEMBL16667894 | 0.81 | BIRC2 (0.42) | MMEACECPA1ACE2DPP4 | |
| SCHEMBL15381259 | 0.80 | DPP4 (0.40) | MMEACECPA1ACE2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137852-A1 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | Cadila Corporate Campus (IN) | 2013-05-30 | — | — | US | disclosed |
| WO-2012017391-A2 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | CADILA PHARMACEUTICALS LIMITED (IN) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137852-A1 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | DPP4, DPP7, DPP3 | MME 65/4885ACE 17/4885CPA1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.